AARD

Aardvark Therapeutics

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

29

Business Summary

Aardvark Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing novel small molecule therapies. Its pipeline targets metabolic diseases, chronic inflammation, and other areas with significant unmet medical needs.

 


Analyze AARD on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$270

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

2.2

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$2.53

Next Year EPS Growth Estimate

-$3.59

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-39.80%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze AARD on TradingView

Gainseekers Quantitative Analysis

Summary

Aardvark Therapeutics is a biotechnology company with a market capitalization of $270 million. The company is currently unprofitable, with an EPS of -$2.53 and a Return on Equity of -39.80%. The company currently has a Debt / Equity ratio of 0.

AI Exposure / Tech Reliance

No data is available regarding the company's AI exposure or technology reliance.

The Bull Case

The analyst Consensus Rating is a strong 1.23 with a Mean Consensus Target Price of $32.64, and the company maintains a clean balance sheet with a Debt / Equity ratio of 0. Institutional Ownership is high at 59.20%, indicating professional investor confidence.

The Bear Case

The company is unprofitable with an EPS of -$2.53, which is estimated to worsen to -$3.59 next year. A high Short % of Float at 12.50% and a negative Return on Equity of -39.80% highlight significant risk and investor skepticism.

Market Sentiment & Smart Money

Short Interest %

12.50%

Analyst Consensus

1.23

Average Analyst Price Target

$32.64

Institutional Ownership %

59.20%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.